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Vascular endothelial growth factor (VEGF) receptors consist of three cell-membrane type receptors (VEGFR-1, VEGFR-2 and
VEGFR-3), and soluble form of VEGFR-1 (sVEGFR-1), an intrinsic negative counterpart of the VEGF. In this study, we measured
intratumoral protein levels of free and total VEGF, VEGFR-2 and sVEGFR-1 from 202 primary breast cancer tissues and examined
their prognostic values. A significant inverse correlation was found between free or total VEGF and oestrogen receptor (ER) status
(P¼0.042 and 0.032, respectively). A univariate analysis showed that low sVEGFR-1 and high total VEGF were significantly associated
with poor prognosis in disease-free survival (DFS) and overall survival (OS). The ratio of sVEGFR-1 to total VEGF was a strong
prognostic indicator (DFS: P¼0.008; OS: P¼0.0002). A multivariate analysis confirmed the independent prognostic values of total
VEGF and the ratio of sVEGFR-1 to total VEGF. In subgroup analysis, total VEGF was a significant prognostic indicator for ER-positive
tumours but not for ER-negative tumours, whereas sVEGFR-1 was significant for ER-negative tumours but not for ER-positive
tumours. In conclusion, the intratumoral sVEGFR-1 level, VEGF level and the ratio of sVEGFR-1 to total VEGF are potent prognostic
indicators of primary breast cancer, and might be relevant to ER status.
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Vascular endothelial growth factor (VEGF) and its receptors are
essential for neovascularisation in cancer. Numerous studies have
indicated that intratumoral VEGF expression is significantly
correlated with microvessel density and poor prognosis in a
variety of human solid cancers including breast cancer, brain
tumours, head and neck cancer and gastrointestinal cancer (Toi
et al, 2001; Ferrara et al, 2003). The prognostic value of VEGF has
been confirmed not only in immunohistochemical studies but also
in other studies using enzyme-linked immunosorbent assay
(ELISA) and Northern blotting. In most clinical studies that
examined the prognostic value of VEGF in primary breast cancer,
intratumoral VEGF expression was a significant marker of poor
prognosis in both node-negative and node-positive subgroups
(Gasparini, 2000). Thus, these studies concluded that intratumoral
VEGF status is an independent prognostic indicator of primary
breast cancer.
VEGF binds to two types of cell-membrane receptors, the VEGF
receptor (VEGFR)-1 and VEGFR-2 located in the endothelium, and
stimulates endothelial migration, proliferation, permeability and
survival (Ferrara and Alitalo 1999; Shibuya, 2001). In addition to
these two receptors, a soluble form of VEGFR-1 (sVEGFR-1), a
naturally occurring and alternatively spliced variant of sVEGFR-1,
functions as a high-affinity receptor of VEGF (Kendall and
Thomas, 1993; Kendall et al, 1996). Since sVEGFR-1 is a secretory
protein, it is an intrinsic negative counterpart of VEGF signalling.
Recombinant sVEGFR1 binds to all isoforms of VEGF and inhibits
VEGF-induced endothelial cell proliferation. Gene therapies
involving sVEGFR-1 significantly suppress tumour growth in
animal experimental models (Goldman et al, 1998; Takayama et al,
2000; Mahasreshti et al, 2001; Hoshida et al, 2002; Sako et al, 2004).
Kendall et al (1996) found that sVEGFR1 is abundant in all
identified VEGFR-1 cDNAs from human primary endothelial cells.
In our preliminary study using primary breast cancer tissues,
sVEGFR1 was frequently coexpressed with VEGF, and the
intratumoral balance between sVEGFR1 and VEGF levels showed
a significant relationship with survival (Toi et al, 2002). According
to a recent report on brain tumours, the ratio of sVEGFR-1 to
VEGF is significantly decreased in glioblastomas compared with
astrocytomas, which indicates the importance of sVEGFR-1
expression in brain tumour growth (Lamszus et al, 2003). It is
therefore crucial to investigate the relationship between VEGF and
its receptors including sVEGFR-1. Previous studies have indicated
that intratumoral sVEGFR-1 levels are frequently elevated in
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shuman tumour tissues, although the precise upregulation mecha-
nism involving sVEGFR-1 in cancer is largely unknown.
Recently, we have developed a more sensitive sVEGFR-1 ELISA
system in addition to new methodologies that permit the separate
measurement of free VEGF, which is unbound to the receptors,
and total VEGF, which includes both bound and unbound
molecules to receptors. In this study, we measured total and free
VEGF, sVEGFR-1 and VEGFR-2, as well as Her-2/neu and
thymidine phosphorylase (TP) levels in breast tumour cytosols
quantitatively and then evaluated those prognostic values. The
information from this study is useful not only for assessing
the prognostic value of these markers but also for considering the
clinical implications of future anti-VEGF therapies paradigm.
MATERIALS AND METHODS
Patient population
We randomly selected tissues from 202 patients with operable
primary breast cancer who underwent modified radical or partial
mastectomy with full dissection of their axillary lymph nodes at
the Tokyo Metropolitan Komagome Hospital from 1996 to 1999
with an average follow-up period of 64.0 months and a range of
1.3–93.2 months. Representative samples of the tumour specimens
were immediately frozen in liquid nitrogen after surgical resection
and stored at  801C until preparation for ELISA. Pathological
examinations were performed on formalin-fixed, paraffin-em-
bedded specimens. The main characteristics of the patients and
adjuvant hormone and chemotherapy details are described in
Table 1. All patients signed an informed consent according to a
protocol approved by the ethics committee of the hospital.
Adjuvant therapy and patient follow-up Indications for and the
schedule of adjuvant treatment were decided based on the patient
characteristics including axillary nodal involvement (n), tumour
size (T), age and oestrogen receptor (ER). Polychemotherapy
including six cycles of CA(E)F (cyclophosphamide, adriamycin/
epirubicin and 5-fluorouracil (5-FU)) was given to node-positive
patients under the age of 60 years, and FU derivatives were given to
the remaining node-positive and high-risk node-negative patients.
Tamoxifen was given to hormone receptor-positive patients
without a history of thrombosis or liver dysfunction for 5 years
and additional LH-RH agonist therapy was undertaken for 2 years
for premenopausal cases. The patients received radiation to the
remaining breast if partial mastectomy was performed, and to the
chest wall and draining lymph nodes if more than four lymph
nodes were involved. Post-treatment surveillance was carried out
according to general practice for breast cancer patients at our
institute. Briefly, for the first 5 years physical examinations,
haematology and blood chemistry analyses were performed every 3
months, chest X-rays were taken every 6 months and mammo-
graphy was performed annually. Thereafter, physical, blood and
chest X-ray examinations were performed every 6–12 months, and
annual mammography was continued. If tumour relapse was
suspected, the patient underwent intensive work-up including
chest/abdominal computed tomography scans, isotopic bone
scans, bone radiography or histological examination. Survival
analysis was performed on 186 cases excluding six patients with
ductal carcinoma in situ (DCIS) and 10 patients who did not show
up for the follow-up. The outcomes examined included overall
survival (OS) and disease-free survival (DFS), which were
calculated from the date of surgery. Overall survival was calculated
from the date of surgery to last contact for living patients. Disease-
free survival was defined as the period from the date of surgery to
the confirmed tumour relapse date for relapsed patients and from
the date of surgery to the date of the last follow-up for disease-free
patients.
Histopathologic analysis
Representative sections from all primary tumours were reviewed
and analysed by pathologists. The special morphologic features
examined included grade, lymph vessel/blood vessel involvement
and the number of lymph nodes involved.
Sample preparation Breast tumour tissue samples were treated
with two different types of lysis buffer. For the measurement of
sVEGFR-1 and TP protein, tissue samples were homogenised in a
solution of 10mM Tris-HCl buffer (pH 7.4) containing 15mM NaCl,
1.5mM MgCl2,5 0 mM potassium phosphate and a protease-
inhibitor cocktail. For all other ELISA measurements, samples
were individually homogenised in a 10-fold volume of RIPA buffer
(0.1% SDS, 1% Tween 20, 0.5% Na-deoxycholate, protease-
inhibitor cocktail in phosphate-buffered saline, pH 7.4) and then
centrifuged at 14000g for 20min. The supernatants were then
stored at  801C until use. A portion of each supernatant was used
for protein concentration measurement according to standard
protocols (BCA assay, Pierce, Rockford, IL, USA).
Enzyme-linked immunosorbent assay
Total VEGF protein concentrations in the tumour cytosols were
measured using VEGF ELISA kits (R&D Systems, Minneapolis,
MN, USA). The measurements were conducted according to the
Table 1 Patients characteristics
Number of patients (%)
Patients enrolled 202
Median age (years) 55, range 30–86
Menopausal status
Pre 86 (42.6)
Post 116 (57.4)
Tumour size (cm)
o2 26 (12.9)
2–5 125 (61.9)
45 51 (25.2)
Nodal involvement
  94 (46.5)
+ 108 (53.5)
ER
Positive 110 (54.5)
Negative 92 (45.5)
PgR
Positive 105 (52.0)
Negative 97 (48.0)
Hormonal receptor
ER+ and PR+ 79 (39.1)
ER+ or PR+ 56 (27.7)
ER  and PR  67 (33.2)
Nuclear grade
1 39 (19.3)
2 99 (49.0)
3 64 (31.7)
Recurrence
+ 57 (28.2)
  145 (71.8)
Adjuvant therapy
CAF (CEF) 54 (26.7)
CMF (CF) 18 (8.9)
FU derivatives 38 (18.8)
Tamoxifen 119 (58.9)
LH-RH 10 (5.0)
ER¼oestrogen receptor; PgR¼progesterone receptor; CAF (CEF)¼cyclo-
phosphamide, adriamycin or epirubicin and 5-FU; CMF (CF)¼cyclophos-
phamide, methotrexate and 5-FU.
VEGF, sVEGFR-1, VEGFR-2 and prognosis in breast cancer
H Bando et al
554
British Journal of Cancer (2005) 92(3), 553–561 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
smethods recommended by the manufacturer. The minimal
detection limit for total VEGF was 31pgml
 1.
A receptor–ligand detection assay was applied to detect free
bioactive VEGF following the basic protocol for total VEGF ELISA,
except that plates were coated with 0.5mgml
 1 sVEGFR-1 (D1–
D6) produced in insect cells (Hornig et al, 1999). This ensured that
no VEGFR-1 complex forms were recognised. For detection,
biotinylated anti-VEGF antibody (R&D Systems, Minneapolis, MN,
USA) was used. The minimal detection limit for free VEGF was
20pgml
 1.
Enzyme-linked immunosorbent assay for sVEGFR-1 was per-
formed as previously reported with modifications to improve
sensitivity (Toi et al, 2002). A human sVEGFR-1 ELISA kit (Bender
MedSystems, Vienna, Austria) was used according to the
manufacturer’s protocol. The minimum detection limit was
100pgml
 1.
The VEGFR-2 protein concentration in tumour lysates was
measured using VEGFR-2 ELISA kits (R&D Systems, Minneapolis,
MN, USA). The measurements were conducted according to the
methods recommended by the manufacturer. The minimal
detection limit for VEGFR-2 was 78pgml
 1.
Her-2/neu was determined using a Her-2/neu (c-erbB-2)
sandwich enzyme immunoassay (Oncogene Science, Cambridge,
MA, USA), which employs a mouse monoclonal antibody for
capture and a different biotinylated mouse monoclonal antibody
for the detection of human neu protein. The capture and detector
reagents specifically bind to the extracellular domain of the neu
protein. The minimal detection limit for Her-2/neu was 24pgml
 1.
Thymidine phosphorylase levels were also determined by a
colorimetric ELISA. This sandwich immunoassay used two anti-
human TP monoclonal antibodies (Nippon Roche Research
Center, Kamakura, Japan; 104B and 232-2). The minimal
detectable concentration was 1.25ngml
 1.
Levels of ER and progesterone receptor (PgR) were determined
using enzyme immunoassay systems from the Otsuka Assay
Institute (Tokushima, Japan) as previously reported. The cutoff
value of enzyme immunoassay for ER and PgR was 10fmolmg
 1
protein.
All protein level measurements made by ELISA were performed
in duplicate.
Statistical methods
The correlation between two factors was evaluated using the
Spearman’s correlation coefficient by rank and unpaired groups
were compared using the Student’s t-test. Univariate and multi-
variate Cox regression analyses were carried out to assess potential
prognostic indicators of DFS and OS. These features included ER
and PgR status, tumour grade (low vs intermediate and high
grade), tumour size (5 vs 45cm), axillary lymph node involve-
ment (positive vs negative), lymph vessel involvement (positive vs
negative), blood vessel involvement (positive vs negative), total
VEGF protein concentration (omean vs 4mean), free VEGF
protein concentration (omean vs 4mean), sVEGFR-1 protein
concentration (o0.435 vs 40.435ngmg
 1 protein), VEGFR-2
protein concentration (mean vs 4mean), Her-2/neu protein
concentration (omean vs 4mean), TP protein concentration
(mean vs 4mean) and sVEGFR-1/total VEGF (o0.5 vs X0.5). All
clinical and biological parameters regardless of whether they were
statistically significant as seen by the univariate analysis were
included in the multivariate analysis. Variables that exhibited
statistically significant effects were then retained and the others
were dropped.
Multivariate analysis resulted in a final model of five prognostic
variables for DFS and four prognostic variables for OS. Models
were then generated based on the presence or absence of these
variables and constructed to assess the relative risk for relapse and
death.
Standard Kaplan–Meier and Cox regression methods were
applied for survival analysis using the StatView statistical software
Version 5.0 (SAS Institute, Cary, NC, USA). All significance testing
was two-sided, where log-rank statistics and Wald statistics were
used for univariate and multivariate analysis, respectively.
Differences for Po0.05 were considered to be statistically
significant. The last follow-up date was 31st March 2004.
RESULTS
Patient characteristics
The patient characteristics are listed in Table 1. The median age at
diagnosis was 55 years with a range of 30–86 years. Five patients
who presented with DCIS were excluded from the survival analysis.
A total of 110 (54%) underwent adjuvant chemotherapy, and 64%
of the patients with positive receptor underwent adjuvant
hormonal therapy. In all, 66% of the tumours were ER positive
and/or PgR positive, and 81% were intermediate or high-grade
tumours.
The protein concentrations of total VEGF, free VEGF, sVEGFR-
1, VEGFR-2, TP and Her-2/neu in breast tumour tissue extracts
determined by ELISA are listed in Table 2. The correlations
between each factor and clinico-pathological parameters were
analysed. Total and free VEGF levels were significantly higher in
ER-negative tumours, and free VEGF levels were also higher
in PgR-negative tumours. Soluble VEGFR-1 levels were higher in
PgR-negative tumours, and VEGFR-2 showed no statistically
significant correlation with any of the clinico-pathological para-
meters. Her-2/neu was associated with a larger tumour size, ER
negativity and high nuclear grade (P¼0.01, 0.04 and 0.03,
respectively). There was a significant correlation of the protein
levels between total VEGF and free VEGF (Po0.001, r¼0.905),
total VEGF and sVEGFR-1 (Po0.001, r¼0.278), free VEGF and
sVEGFR-1 (Po0.001, r¼0.251), sVEGFR-1 and VEGFR-2
(P¼0.008, r¼0.190), total VEGF and Her-2/neu (P¼0.029,
r¼0.157), free VEGF and Her-2/neu (P¼0.04, r¼0.145), total
VEGF and TP (P¼0.004, r¼0.207), free VEGF and TP (P¼0.017,
r¼0.171) and sVEGFR-1 and TP (Po0.001, r¼0.270), but none
was seen between VEGF and VEGFR-2 by Spearman’s rank
correlation test (data not shown).
To assess the prognostic value of sVEGFR-1 and the ratio of
sVEGFR-1 to total VEGF, we determined the cutoff level according
to a stepwise method that gives the optimal separation between a
low and high risk of relapse as previously described (Toi et al,
2002). The cutoff value for sVEGFR-1 was 0.435ngmg
 1 protein,
which identified 15.6% of the patients enrolled in the survival
analysis as having low sVEGFR-1. For total and free VEGF,
VEGFR-2, TP and Her-2/neu, the cutoff values were determined as
their respective mean values.
According to the combination analysis, the ratio of sVEGFR-1 to
total VEGF concentration (S/V ratio) and its prognostic value were
assessed using a similar stepwise separation method as described
above. Tumours with an associated S/V ratio of 3.0 were
considered to be borderline for achieving a prognostic value for
survival analysis. A value of 0.5 was decided on as the cutoff value,
with 8.6% of the patients having a low S/V ratio with the most
unfavourable prognosis (Table 3).
For univariate analyses, patients with low-grade tumours
(P¼0.002), tumours less than 5cm in size (P¼0.0001), no lymph
node involvement (P¼0.0001), less vessel involvement (P¼0.01–
0.001), low total VEGF level (P¼0.002), low free VEGF level
(P¼0.047), high sVEGFR-1 level (P¼0.04) and a high S/V ratio
(P¼0.008) experienced favourable DFS (Table 3). Overall survival
was favourable for patients with negative PgR status (P¼0.017),
low-grade tumours (P¼0.011), tumours less than 5cm in size
(P¼0.0002), no lymph node involvement (P¼0.0005), less vessel
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sTable 2 Quantitation of total and free VEGF, sVEGFR-1, VEGFR-2, Her-2/neu and TP proteins in primary breast cancer tumour cytosol
Total VEGF Free VEGF sVEGFR-1 VEGFR-2 TP Her-2/neu
No. Mean 95% CI P Mean 95% CI P Mean 95% CI P Mean 95% CI P Mean 95% CI P Mean 95% CI P
Patients enrolled 202 0.532 0.432–0.632 0.135 0.118–0.152 0.949 0.849–1.048 0.105 0.098–0.112 194.9 181.1–209.9 13.057 10.147–15.867
Menopause
Pre 86 0.534 0.420–0.644 NS 0.132 0.106–0.170 NS 0.896 0.740–1.053 NS 0.102 0.087–0.131 NS 194.2 177.9–219.1 NS 15.265 10.189–20.340 NS
Post 116 0.530 0.416–0.644 0.141 0.113–0.156 0.994 0.858–1.130 0.108 0.098–0.123 195.3 172.8–213.4 11.244 8.005–14.483
Tumour size
T1 26 0.532 0.420–0.644 NS 0.102 0.075–0.128 NS 0.917 0.737–1.97 NS 0.103 0.089–0.117 NS 196.7 166.3–227.1 NS 11.916 5.163–18.669
T2 125 0.536 0.425–0.647 0.141 0.115–0.168 0.962 0.823–1.097 0.107 0.095–0.119 198.6 178.7–218.4 10.785 7.563–14.007
T3 or more 51 0.520 0.356–0.684 0.136 0.117–0.155 0.956 0.714–1.198 0.105 0.085–0.125 187.0 155.6–218.5 19.290 12.006–26.575 0.01
a
Nodal status
n  94 0.550 0.462–0.638 NS 0.139 0.116–0.163 NS 0.954 0.852–1.055 NS 0.106 0.096–0.116 NS 201.9 188.9–214.9 NS 11.983 8.285–15.682 NS
n+ 108 0.516 0.392–0.640 0.133 0.102–0.163 0.899 0.751–1.047 0.104 0.091–0.117 187.6 166.5–208.5 13.860 9.568–18.152
Hormonal receptor
ER+ 120 0.458 0.401–0.515 0.042 0.119 0.098–0.140 0.032 0.905 0.784–1.027 NS 0.109 0.098–0.121 NS 201.0 183.6–218.4 NS 10.924 7.985–13.864 0.048
ER  82 0.621 0.464–0.778 0.159 0.092–0.227 1.031 0.849–1.213 0.102 0.087–0.117 186.9 161.5–212.3 16.117 10.473–21.761
PgR+ 105 0.450 0.342–0.559 0.055 0.112 0.087–0.138 0.012 0.81 0.695–0.926 0.011 0.103 0.094–0.112 NS 190.2 181.0–210.5 NS 12.170 7.957–16.384 NS
PgR  97 0.600 0.491–0.710 0.160 0.133–0.186 1.094 0.933–1.254 0.110 0.098–0.122 200.3 179.5–221.1 13.817 9.870–17.765
Recurrence
+ 57 0.658 0.516–0.800 NS 0.163 0.129–0.197 NS 0.942 0.741–1.144 NS 0.103 0.082–0.123 NS 203.6 169.8–237.7 NS 13.612 10.285–16.939 NS
  145 0.482 0.3801–0.584 0.126 0.104–0.148 0.941 0.825–1.057 0.107 0.098–0.116 192.8 177.1–208.6 11.491 5.617–17.366
Nuclear grade
1 39 0.531 0.450–0.612 NS 0.104 0069–0.138 NS 0.868 0.849–1.048 NS 0.110 0.091–0.129 NS 186.9 168.4–205.4 NS 12.965 6.758–19.172
2 99 0.503 0.400–0.606 0.141 0.112–0.170 0.917 0.772–1.062 0.099 0.089–0.109 200.8 180.9–220.7 10.323 6.969–13.678
3 64 0.578 0.468–0.688 0.148 0.116–0.180 1.075 0.864–1.286 0.110 0.095–0.125 205.6 178.4–232.8 16.947 10.680–23.214 0.032
b
Intratumoral total and free VEGF, sVEGFR-1, VEGFR-2, TP, Her-2/neu, ER and PR protein levels were measured by quantitative ELISA and enzyme immunoassay (see ‘Materials and Methods’). The results reflect the mean values, 95%
CI and P-value. Levels of ER and PgR more than 10fmolmg
 1 total protein were considered positive (+) and less than 5fmolmg
 1 total protein negative ( ). The correlations between each biological factor and clinico-pathological
parameters were analysed using Student’s t-test. Differences at Po0.05 were considered to be statistically significant. NS¼not significant.
aStatistically significant between T2 and T3.
bStatistically significant between nuclear grade 2
and 3.
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sinvolvement (P¼0.05–0.008), low total VEGF level (P¼0.006),
high sVEGFR-1 level (P¼0.05) and a high S/V ratio (P¼0.0002).
Figure 1 shows DFS curves of the tumour-related prognostic
features total VEGF and sVEGFR-1. Oestrogen receptor status and
VEGFR-2, Her-2/neu and TP level did not have a statistically
significant effect on patient outcome in the univariate analyses.
When we assessed the prognostic value of angiogenesis-related
factors in the subgroups divided by ER status, total VEGF was a
significant prognostic factor for ER-positive group (P¼0.0003)
and not for ER-negative group (P¼0.120) (Table 4 and Figure 1).
In contrast, within the ER-negative group, sVEGFR-1 and the S/V
ratio were found to be strong prognostic indicators (P¼0.001 and
0.0001, respectively), but this was not the case for the ER-positive
group. In particular, all patients with ER-negative and low S/V
ratio tumours relapsed within 4 years after surgery (Figure 1).
There was also a statistically significant benefit for OS with high
sVEGFR-1 or a high S/V ratio for the ER-negative group (P¼0.03
and 0.0002, respectively), but not for the ER-positive group.
Figure 1 shows the DFS curves for total VEGF, sVEGFR-1 and the
S/V ratio for the ER-positive population (n¼111) and ER-negative
subpopulation (n¼75). The results of other subgroup analyses
divided by total VEGF status, TP status and Her-2/neu status are
summarised in Table 4.
All tumour- and clinico-pathological-related parameters regard-
less of whether they were statistically significant as seen by
univariate analysis were included in the multivariate analysis.
Variables showing statistically significant effects were retained and
the others were dropped. The resulting multivariate analysis
Table 3 Univariate analysis of clinico-pathological and tumour biologic factors for DFS and OS
DFS OS
Parameter n (total 186) P Hazard ratio 95% CI P Hazard ratio 95% CI
Clinical features
ER
Positive 111 0.503 0.835 0.493–1.415 0.098 0.604 0.332–1.099
Negative 75 Baseline Baseline
PgR
Positive 92 0.051 0.584 0.340–1.003 0.017 0.461 0.243–0.872
Negative 94 Baseline Baseline
Nuclear grade
1 33 0.002 0.111 0.026–0.466 0.011 0.075 0.010–0.556
2 and 3 153 Baseline Baseline
Tumour size (cm)
1–5 146 0.0001 0.224 0.131–0.384 0.0002 0.313 0.170–0.579
5 or more 42 Baseline Baseline
Nodal involvement
n+ 104 Baseline Baseline
n  84 0.0001 0.207 0.104–0.410 0.0005 0.271 0.130–0.565
Lymph vessel (ly) involvement
ly positive 140 Baseline Baseline
ly negative 46 0.001 0.107 0.026–0.438 0.008 0.07 0.010–0.512
Blood vessel (v) involvement
v positive 131 Baseline Baseline
v negative 55 0.016 0.396 0.187–0.842 0.05 0.421 0.177–1.002
Biological features
Total VEGF
High (40.532ngmg
 1 protein) 64 0.002 2.231 1.306–3.811 0.006 2.278 1.233–4.206
Low (o0.532ngmg
 1 protein) 122 Baseline Baseline
Free VEGF
High (40.135ngmg
 1 protein) 71 0.047 1.72 0.999–2.962 0.204 1.488 0.803–2.758
Low (o0.135ngmg
 1 protein) 115 Baseline Baseline
SVEGFR-1
High (40.435ngmg
 1 protein) 29 0.040 0.526 0.282–0.983 0.05 0.527 0.258–1.075
Low (o0.435ngmg
 1 protein) 157 Baseline Baseline
VEGFR-2
High (40.105ngmg
 1 protein) 119 0.316 0.762 0.447–1.299 0.883 1.047 0.563–1.947
Low (o0.105ngmg
 1 protein) 67 Baseline Baseline
Her-2/neu
High (413.5ngmg
 1 protein) 41 Baseline Baseline
Low (o13.5ngmg
 1 protein) 145 0.362 1.394 0.682–2.848 0.753 0.889 0.426–1.854
TP
High (4194.9ngmg
 1 protein) 97 0.785 0.928 0.541–1.590 0.955 0.983 0.533–1.813
Low (o194.9ngmg
 1 protein) 89 Baseline Baseline
S/V ratio
High (X0.5) 170 0.008 0.368 0.186–0.731 0.0002 0.267 0.127–0.561
Low (o0.5) 16 Baseline Baseline
Prognostic parameters evaluated included ER and PR status (o10fmolmg
 1 protein vs more than 10fmolmg
 1 protein), primary tumour size, axillary lymph node involvement,
total VEGF level, free VEGF level, sVEGFR-1 level, VEGFR-2 level, Her-2/neu protein level, TP level and S/V ratio (sVEGFR-1/total VEGF ratio). For total and free VEGF, VEGFR-2
and Her-2 protein levels, cutoff values were determined as mean values. For sVEGFR-1 and S/V ratio, cutoff values were determined according to a stepwise method (see
Results). The median follow-up was 64 months. Survival analysis was performed on 186 cases excluding six patients with ductal carcinoma in situ and 10 patients who did not
show up for the follow-up. The prognostic significance was assessed using the log-rank test. All P-values are two-sided. Hazard ratio indicated Cox model hazard ratio.
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VEGF (Po0.001 and P¼0.043), a high S/V ratio (P¼0.002 and
0.003), pathological low grade (P¼0.015 and 0.034), tumour less
than 5cm in size (P¼0.002 and 0.038) and negative nodal
involvement (P¼0.001 and 0.002, respectively) (Table 5). Soluble
VEGFR-1 alone did not result in improved DFS or OS.
DISCUSSION
Soluble VEGFR1 levels are frequently elevated in human breast
cancer tissues. Out of 202 tumours, 155 contained higher
concentrations of sVEGFR-1 than those of total VEGF. A recent
study of the relationship between circulating sVEGFR-1 levels and
preeclampsia reported that increased sVEGFR-1 is significantly
associated with the development of preeclampsia, suggesting that
immunodetectable sVEGFR-1 is biologically active (Levine et al,
2004). Regarding malignancies such as brain tumours or
leukaemia, it was also documented that intratumoral or plasma
sVEGFR-1 level is related to tumour phenotype or prognosis,
suggesting that sVEGFR-1 plays a significant biological role not
only during development or pregnancy but also in neoplasms
(Lamszus et al, 2003; Hu et al, 2004).
Since simultaneous measurement of sVEGFR-1 and VEGFR-1 in
the same sample is technically difficult, we were not able to
compare the concentrations of sVEGFR-1 with those of VEGFR-1
directly. Nevertheless, as a preliminary study, we examined
sVEGFR-1 and VEGFR-1 expressions in human umbilical vein
endothelial cells (HUVECs) and in primary breast tumour tissues
by Western blot using different types of lysis buffers with or
without detergent. Using HUVECs as a positive control for both
VEGFR-1 and sVEGFR-1, we confirmed that in the protein extract
prepared without detergent, only sVEGFR-1 was detectable, and in
contrast, in the protein extract prepared with detergent such as
with RIPA buffer, both VEGFR-1 and sVEGFR-1 were detectable.
We speculated that VEGFR-1 exists on a cell membrane, and the
membrane fraction will not be lysed in a buffer without detergent.
Then we examined expression of sVEGFR-1 and VEGFR-1 by
Western blot analysis in 15 randomly selected primary breast
cancer tissues prepared with different lysis buffers: 11 tumours had
Total cases
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Figure 1 Kaplan–Meier curves for DFS in patients with primary breast cancer by biological markers. Kaplan–Meier curves for DFS in patients with
primary breast cancer by biological markers. Disease free survival in the total cases (n¼186) by VEGF level (A), sVEGFR-1 level (B) and sVEGFR-1/
totalVEGF ratio (S/V ratio; C). Disease free survival in the ER-positive cases (n¼111) by VEGF level (D), sVEGFR-1 level (E) and S/V ratio (F): Disease free
survival in the ER-negative cases (n¼75) by VEGF level (G), sVEGFR-1 level (H) and S/V ratio (I). Levels of VEGF protein more than 0.532ngmg
 1 total
protein were considered high (solid line) and less than 0.532ngmg
 1 total protein negative (dotted line) in (A, D and G). Soluble VEGFR-1 protein levels
more than 0.135ngmg
 1 total protein were considered high (solid line) and less than 0.135ngmg
 1 total protein negative (dotted line) in (B, E and H). S/V
ratio more than 0.5 was considered high (solid line) and less than 0.5 negative (dotted line) in (C, F and I). (A) The hazard ratio (HR)¼2.23 (95%
confidence interval (CI)¼1.31–3.81, P¼0.002 using the log-rank test) in favour of total VEGF-low group. (B)H R¼0.526 (95% CI¼0.28–0.98, P¼0.04
using the log-rank test) in favour of total sVEGFR-1-high group. (C)H R¼0.368 (95% CI¼0.19–0.73, P¼0.008 using the log-rank test) in favour of S/V
ratio-high group. (D) In ER-positive subgroup, HR¼3.800 (95% CI¼1.74–8.31, P¼0.0003 using the log-rank test) in favour of total VEGF-low group. (H)
In ER-negative subgroup, HR¼0.269 (95% CI¼0.11–0.53, P¼0.001 using the log-rank test) in favour of sVEGFR-1-high group. (I) In ER-negative
subgroup, HR¼0.114 (95% CI¼0.04–0.30, P¼0.0001 using the log-rank test) in favour of sVEGFR-1-high group.
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ssVEGFR-1 expressions and its expressions were more dominant
than VEGFR-1 expressions, and the concentration of sVEGFR-1
measured by ELISA was well correlated (data not shown). With
samples treated without detergent, VEGFR-1 band was not
detected in all cases. Although we have not examined all the cases
that we used in the current study by Western blot analysis, the
measurement of sVEGFR-1 expression with appropriate lysis
buffer is meaningful with this ELISA system.
Total VEGF was determined to be a potent and independent
prognostic indicator in both node-negative and node-positive
cancers as reported in the previous studies (Toi et al, 2001; Ferrara
et al, 2003). No significant prognostic value of free VEGF was
observed in this study. It is difficult to explain why only total VEGF
provides significant prognostic value but not free VEGF. Total
VEGF concentration is a useful marker for predicting survival or
disease progression. The current study using a highly sensitive
sVEGFR-1 ELISA system confirmed that sVEGFR-1 is a significant
prognostic indicator. In particular, we discovered that low
sVEGFR-1 was related to an unfavourable prognosis, which was
a slightly different result from that we had in a previous study with
a relatively low-sensitivity sVEGFR-1 ELISA system, where we
found a prognostic value of high sVEGFR-1 concentrations for
favourable prognosis (Toi et al, 2002). The significance of the ratio
of sVEGFR-1 to total VEGF (S/V ratio) as a prognostic marker was
reconfirmed in this larger size of analysis. Particularly, a low S/V
ratio was associated with unfavourable prognosis. Since sVEGFR-1
protein is estimated to be produced by both tumour cells and
stromal cells in breast cancer microenvironment, it would be
important to analyse the regulatory mechanisms of this balance
more thoroughly.
In the subgroup analyses, we found that low sVEGFR-1
expression was significantly related to poor prognosis for ER-
negative subgroup but not for ER-positive subgroup. The
prognostic value of S/V ratio also significantly associated with
ER negativity, and the correlation was more relevant than
sVEGFR-1 status alone. It is reported that total VEGF expression
is related to a poor prognosis in ER-positive patients rather than
ER-negative patients (Linderholm et al, 2000; Foekens et al, 2001;
Buteau-Lozano et al, 2002; Manders et al, 2003). Therefore, it is
important to consider why the prognostic value of sVEGFR-1 or
S/V ratio was associated with ER-negative status. Several explana-
tions might be possible. First, the sensitivity of endothelial cells to
VEGF might be different between ER-positive tumours and ER-
negative tumours. Several reports discussed that ER-positive and
ER-negative tumours display remarkably different gene expression
phenotypes (Gruvberger et al, 2001). Also, ER-negative tumour
cells produced larger amounts of growth factors and cytokines that
can stimulate various types of cells including endothelial cells
(Bando et al, 2003). Second, adjuvant therapies, especially post-
operative hormone therapy, might cause a difference in the
survival analysis between ER-positive and ER-negative subgroups.
It is known that hormone treatments such as tamoxifen can
downregulate VEGF expression in hormone-sensitive breast
tumour cells or tumour tissues (Garvin and Dabrosin, 2003). In
addition, it was recently documented that sVEGFR-1 was inducible
in normal breast cell line and human breast cancer cell line, MCF-
7, with hormone-dependent property in response to anti-oestrogen
treatments (Elkin et al, 2004). In those cells, oestrogen was a potent
downregulator of sVEGFR-1, and ER antagonism blocked the
action dramatically. In the present study using nontreated primary
tumours, sVEGFR-1 levels were significantly higher in PgR-
negative tumours rather than PgR-positive tumours, which seems
to support the idea that sVEGFR-1 is downregulated in purely
hormone-dependent tumours such as ER-positive and PgR-
positive tumours. According to these data, it might be possible
to hypothesise that adjuvant hormonal treatments may suppress
disease progression in patients having low S/V ratio, which is
basically associated with poor survival, by modulating those
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sexpressions. In ER-negative patients, theoretically it does not
happen. Many other possibilities could be raised to explain this
translational research question.
Another important finding observed in subgroup analyses is
that the total VEGF and sVEGFR-1 levels as well as the S/V ratio
exhibited significant prognostic importance for low Her-2/neu
tumours but not for high Her-2/neu tumours (Table 4). Transfec-
tion of the Her-2/neu gene enhances VEGF expression in breast
cancer experimental models (Yen et al, 2000). In this study, the
intratumoral concentrations of Her-2/neu were significantly
correlated with those of VEGF. The regulatory mechanism of
VEGF and sVEGFR-1 expressions could be different between
Her-2/neu-positive and Her-2/neu-negative subgroups.
As to the regulatory mechanism of sVEGFR-1, several factors
such as growth mediators and hypoxia are reported to induce the
expression of VEGFR-1 and sVEGFR-1 in endothelial cells
(Barleon et al, 1997). Among these inducers, hypoxia might be a
key factor especially, because it is capable of regulating the
expressions of multiple angiogenesis-related molecules simulta-
neously (Griffiths et al, 1997; Bando et al, 2003). It was found in
this study that the intratumoral concentration of sVEGFR-1
significantly correlated with those of VEGFR-2, total VEGF, free
VEGF and TP. Therefore, it is interesting to know the relationship
with the markers of hypoxia in future analysis, and to understand
the machinery of alternative splicing of sVEGFR-1 in both tumour-
associated stromal cells and hormone-dependent cancer cells.
In conclusion, the intratumoral concentration of sVEGFR-1 and
VEGF and the ratio of sVEGFR-1 to total VEGF were potent
prognostic indicators in 202 primary breast tumours in our study.
The expression level and the balance between VEGF and sVEGFR-1
molecules were thought to be important to understand the
hormone dependency of breast cancer and the sensitivity or
resistance to hormonal therapy. Recently, it was clinically
demonstrated that anti-VEGF therapy brings survival benefit to
cancer patients in colorectal cancer patients (Hurwitz et al, 2004).
We speculate that the determination of VEGF and sVEGFR-1 will
also be useful to distinguish anti-VEGF therapy-sensitive tumours
from less sensitive tumours. Eventually, the quantification of
VEGF and its related molecules will be important for under-
standing the tumour growth machinery, the disease progression
and the survival prediction of primary breast cancer and for
considering treatment strategies with hormonal therapies and
antiangiogenesis therapies.
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